BioNTech price target lowered to $147 from $150 at BofA

BofA lowered the firm’s price target on BioNTech (BNTX) to $147 from $150 and keeps a Buy rating on the shares. On the Q4 call, the firm will look for updates to better understand the Comirnaty franchise and revenue trajectory in 2025, but highlights that the focus has shifted from the COVID franchise to the maturing oncology pipeline, which it sees as “the key long-term value driver.”